IMMUNOCORE HLDGS ADS/1 (6YG) — Financial Flexibility Index

Latest as of December 2025: -0.04x

IMMUNOCORE HLDGS ADS/1 (6YG) has a Financial Flexibility Index of -0.04x as of December 2025. Free cash flow of €-29.77 Million (operating CF €-32.66 Million minus capex €2.88 Million) represents 0% of total liabilities (€686.24 Million). Also explore net asset momentum of IMMUNOCORE HLDGS ADS/1 to track the company's year-over-year net asset growth rate.

Financial Flexibility Index

-0.04x
Free Cash Flow / Total Liabilities

Free Cash Flow

€-29.77 Million
Operating CF − Capex

Total Liabilities

€686.24 Million
EUR

Capital Expenditures

€2.88 Million
EUR

IMMUNOCORE HLDGS ADS/1 Financial Flexibility Index (2022–2025)

Historical Financial Flexibility Index trend for IMMUNOCORE HLDGS ADS/1 across 4 annual periods. Check IMMUNOCORE HLDGS ADS/1 (6YG) strategic asset index to assess the company's strategic physical and investment asset allocation.

Annual Financial Flexibility Index for IMMUNOCORE HLDGS ADS/1 (2022–2025)

Year-by-year free cash flow to debt coverage for IMMUNOCORE HLDGS ADS/1. For the full company profile including market capitalisation, see 6YG stock market capitalisation.

Year Flexibility Index Free Cash Flow (EUR) Operating CF Total Liabilities YoY Change
2025 -0.01x €-6.37 Million €-10.71 Million €686.24 Million ▼ -119.3%
2024 0.05x €31.23 Million €26.06 Million €648.79 Million ▲ +31.3%
2023 0.04x €8.37 Million €2.94 Million €228.16 Million ▲ +114.7%
2022 -0.25x €-47.01 Million €-49.21 Million €187.86 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities